Brokerages Set uniQure N.V. (NASDAQ:QURE) Target Price at $41.33

uniQure N.V. (NASDAQ:QURE) has been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $43.25.

A number of analysts have recently commented on QURE shares. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of uniQure in a research note on Tuesday. Chardan Capital boosted their price objective on shares of uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Barclays began coverage on shares of uniQure in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd.

uniQure Stock Down 3.5%

Shares of uniQure stock opened at $16.94 on Tuesday. The business has a fifty day simple moving average of $21.53 and a 200 day simple moving average of $29.49. The stock has a market cap of $1.06 billion, a PE ratio of -4.91 and a beta of 0.73. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Research analysts predict that uniQure will post -3.75 EPS for the current year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

Insider Buying and Selling at uniQure

In related news, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 81,399 shares of company stock worth $1,527,645 in the last three months. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors have recently modified their holdings of the business. Swiss National Bank acquired a new stake in uniQure during the 2nd quarter worth approximately $1,080,000. Sanders Morris Harris LLC acquired a new position in shares of uniQure in the third quarter valued at approximately $5,081,000. Vanguard Group Inc. increased its position in shares of uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after acquiring an additional 152,417 shares in the last quarter. Aberdeen Group plc increased its position in shares of uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after acquiring an additional 1,491,486 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.